AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6123277 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine orally at 2200 hours on the evening before surgery and a further 150 mg 1-2 hours before operation (Group A)
Number of subjects: 90
Study 6123277 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine with premedication only (Group B)
Number of subjects: 90
Study 6123277 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 2200 hours and again with premedication on the day of surgery (Group C)
Number of subjects: 90
Study 30621772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive tobacco-related education program
Number of subjects: 0
Study 30621772 — intervention group
Group type: COMPARATOR
Intervention: Non-tobacco-related training
Number of subjects: 0
Study 28687279 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert feedback
Number of subjects: 46
Study 28687279 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 46
Study 26252171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound‐guided TAP blocks using bupivacaine 0.5% 20 mL on each side
Number of subjects: 60
Study 26252171 — intervention group
Group type: COMPARATOR
Intervention: Surgical site infiltration with liposomal bupivacaine 266 mg diluted to 60 mL
Number of subjects: 60
Study 24280881 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (immunosuppressive medications)
Number of subjects: 293
Study 24280881 — intervention group
Group type: EXPERIMENTAL
Intervention: J-pouch surgery
Number of subjects: 293
Study 24280881 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent ileostomy
Number of subjects: 293
Study 24280881 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (incompletely effective)
Number of subjects: 293
Study 21769731 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute all-out rowing test (3-min RT)
Number of subjects: 18
Study 19329822 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin, 20 mg per day
Number of subjects: 17802
Study 19329822 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study 17822465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin OCAS 1.5 mg
Number of subjects: 364
Study 17822465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 364
Study 17822465 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin OCAS
Number of subjects: 364
Study 17822465 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 364
Study 14704596 — intervention group
Group type: EXPERIMENTAL
Intervention: More efficacious statins
Number of subjects: 0
Study 14704596 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (niacin, bile acid sequestrant, ezetimibe)
Number of subjects: 0
Study 12191432 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthQuiz (HQ)
Number of subjects: 1239
Study 12191432 — intervention group
Group type: COMPARATOR
Intervention: Donor Health Assessment Questionnaire (DHAQ)
Number of subjects: 1239
Study 9825271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine (IA) 400 mg
Number of subjects: 40
Study 9825271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8126241 — intervention group
Group type: EXPERIMENTAL
Intervention: Degradable controlled release system containing cetylpyridinium chloride (CPC), 9 mg of CPC applied once daily for 4 weeks.
Number of subjects: 44
Study 8126241 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (identical in formation but without active agent), applied once daily for 4 weeks.
Number of subjects: 44
Study 3081148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined test of anterior pituitary function using four hypothalamic releasing factors and arginine vasopressin (100 micrograms each of corticotrophin releasing factor, growth hormone releasing factor, luteinising hormone releasing hormone, and 200 micrograms of thyrotrophin releasing hormone; 10 pressor units of arginine vasopressin intramuscularly)
Number of subjects: 24
Study 3081148 — intervention group
Group type: COMPARATOR
Intervention: Conventional combined test using insulin together with thyrotrophin releasing hormone and luteinising hormone releasing hormone
Number of subjects: 24
Study 26845753 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day)
Number of subjects: 44
Study 26845753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24856191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACPF paste (MI Paste Plus, GC America, Alsip, IL)
Number of subjects: 30
Study 24856191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23174792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D, 50,000 IU per week for two months
Number of subjects: 26
Study 23174792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23174792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 26
Study 20382432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual assault/abuse
Number of subjects: 10424
Study 20382432 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical assault/abuse
Number of subjects: 10424
Study 20382432 — intervention group
Group type: COMPARATOR
Intervention: Life-threatening trauma
Number of subjects: 10424
Study 20382432 — intervention group
Group type: COMPARATOR
Intervention: Emotional abuse/neglect
Number of subjects: 10424
Study 20382432 — intervention group
Group type: COMPARATOR
Intervention: Major life stress experiences
Number of subjects: 10424
Study 20382432 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a woman
Number of subjects: 10424
Study 20382432 — intervention group
Group type: EXPERIMENTAL
Intervention: Being White (versus non-White)
Number of subjects: 10424
Study 20382432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 10424
Study 18550097 — intervention group
Group type: COMPARATOR
Intervention: Prostate specific antigen (PSA) testing before first biopsy
Number of subjects: 5688
Study 18550097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA) testing before second biopsy
Number of subjects: 5688
Study 18955431 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (12 sessions of 20 minutes each)
Number of subjects: 20
Study 18955431 — intervention group
Group type: COMPARATOR
Intervention: Weekly phone call (control group)
Number of subjects: 20
Study 15539895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 195
Study 11264333 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus 16 sessions of manualized group psychotherapy
Number of subjects: 0
Study 11264333 — intervention group
Group type: COMPARATOR
Intervention: Continued medication only (fluoxetine)
Number of subjects: 0
Study 9497790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion (28.9 +/- 2.1 mu-units/ml)
Number of subjects: 0
Study 9497790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (101.7 +/- 6.8 mu-units/ml)
Number of subjects: 0
Study 9497790 — intervention group
Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 0
Study 8212753 — intervention group
Group type: EXPERIMENTAL
Intervention: lopamidol (Solutrast 300)
Number of subjects: 63
Study 8212753 — intervention group
Group type: COMPARATOR
Intervention: Meglumine iothalamate (Conray 60)
Number of subjects: 63
Study 3092712 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (6 mg/d)
Number of subjects: 90
Study 3092712 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (250 mg/d for 4 weeks, 500 mg/d for 4 weeks, then 750 mg/d thereafter)
Number of subjects: 90
Study 30604188 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (+)
Number of subjects: 132
Study 30604188 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (−)
Number of subjects: 132
Study 29937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Bundle (SB) ACL Reconstruction
Number of subjects: 64
Study 29937346 — intervention group
Group type: COMPARATOR
Intervention: Double-Bundle (DB) ACL Reconstruction
Number of subjects: 64
Study 29937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxitester measurements for both SB and DB
Number of subjects: 64
Study 29937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritic changes and tunnel widening for both SB and DB
Number of subjects: 64
Study 27404027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/d
Number of subjects: 2166
Study 27404027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2166
Study 24178236 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron OCAS 25-400 mg single doses
Number of subjects: 76
Study 24178236 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron OCAS 100-200 mg once daily for 7 days
Number of subjects: 76
Study 24178236 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron OCAS up to 400 mg single doses
Number of subjects: 76
Study 24178236 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron OCAS up to 200 mg multiple doses
Number of subjects: 76
Study 22914520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-day nap (up to 20 minutes); Mean sleep duration: 8.4 +/- 3.0 minutes
Number of subjects: 29
Study 22914520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nap, engaged in conversation)
Number of subjects: 29
Study 19209184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropylmethylcellulose (HPMC) 2.5 g twice daily for 4 weeks
Number of subjects: 13
Study 19209184 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) for 4 weeks
Number of subjects: 13
Study 17618766 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior colporrhaphy, site-specific repair, site-specific repair with Fortagen graft augmentation (specific intervention details not provided)
Number of subjects: 106
Study 15180082 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 14
Study 15180082 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 14
Study 11805614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sygen (two doses)
Number of subjects: 28
Study 11805614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9543170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (25 mg as an i.v. bolus)
Number of subjects: 30
Study 7509381 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/ABVD
Number of subjects: 207
Study 7509381 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 207
Study 2971744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study 2971744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31628863 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone dressings applied to sacrum and heels
Number of subjects: 475
Study 31628863 — intervention group
Group type: COMPARATOR
Intervention: No dressings (control group)
Number of subjects: 475
Study 29337134 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 62
Study 29337134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 27421546 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 0
Study 27421546 — intervention group
Group type: EXPERIMENTAL
Intervention: No General Anesthesia (non-GA)
Number of subjects: 0
Study 27421546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IAT)
Number of subjects: 0
Study 25602901 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckle‐Up Safely program
Number of subjects: 830
Study 23456697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 67
Study 23456697 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study 21917254 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 88
Study 21917254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 18162660 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based pride in Study 2
Number of subjects: 0
Study 18162660 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based sympathy in Study 2
Number of subjects: 0
Study 18162660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pride in Study 3
Number of subjects: 0
Study 18162660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathy in Study 3
Number of subjects: 0
Study 18162660 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilt in all studies
Number of subjects: 0
Study 17056948 — intervention group
Group type: COMPARATOR
Intervention: saline IV (control)
Number of subjects: 400
Study 17056948 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg IV
Number of subjects: 400
Study 17056948 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg IV
Number of subjects: 400
Study 17056948 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of droperidol 1.25 mg and ondansetron 4 mg IV
Number of subjects: 400
Study 17056948 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron, droperidol, or their combination
Number of subjects: 400
Study 11932585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte (CHO) drinks
Number of subjects: 10
Study 11932585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) drinks
Number of subjects: 10
Study 10077192 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G (1-day regimen)
Number of subjects: 30
Study 10077192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5-day regimen)
Number of subjects: 30
Study 7743614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 885
Study 7743614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885
Study 2258346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin plus metronidazole
Number of subjects: 271
Study 2258346 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus metronidazole
Number of subjects: 271
Study 7028532 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofensine (50 mg daily, titrated up to 150 mg)
Number of subjects: 27
Study 7028532 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (reference drug)
Number of subjects: 27
Study 31112652 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonomotor treatment
Number of subjects: 25
Study 28427084 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity and nutritional education (APANE)
Number of subjects: 251
Study 26049702 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular imaging as a biomarker for targeted cancer therapy
Number of subjects: 0
Study 26049702 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging tests integrated in therapeutic clinical trials
Number of subjects: 0
Study 23400602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels in TODAY youth
Number of subjects: 699
Study 23400602 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous activity levels in TODAY youth
Number of subjects: 699
Study 23400602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels in TODAY girls
Number of subjects: 699
Study 21177785 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (D3) at 50,000 IU/wk for 12 weeks
Number of subjects: 33
Study 21177785 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2 (D2) at 50,000 IU/wk for 12 weeks
Number of subjects: 33
Study 19665275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% polyoxyethylene (10) octylphenyl ether with MB solution
Number of subjects: 0
Study 19665275 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% polyoxyethylene (10) octylphenyl ether with MB solution
Number of subjects: 0
Study 19665275 — intervention group
Group type: COMPARATOR
Intervention: MB solution only
Number of subjects: 0
Study 17765762 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure Vessel Sealing System tonsillectomy (LT)
Number of subjects: 161
Study 17765762 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel tonsillectomy (HST)
Number of subjects: 161
Study 17765762 — intervention group
Group type: COMPARATOR
Intervention: Cold knife tonsillectomy (CKT)
Number of subjects: 161
Study 15208517 — intervention group
Group type: EXPERIMENTAL
Intervention: Management development programs
Number of subjects: 0
Study 15208517 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 0
Study 11525552 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection system for soft contact lenses (used by 56 subjects for 1 month)
Number of subjects: 103
Study 11525552 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified how many subjects)
Number of subjects: 103
Study 11525552 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection system for soft contact lenses (used by 13 subjects for 3 months)
Number of subjects: 103
Study 9271481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily)
Number of subjects: 58
Study 9271481 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10 mg daily)
Number of subjects: 58
Study 9271481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 58
Study 9271481 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 58
Study 8511810 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (PROG)
Number of subjects: 0
Study 8511810 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 8511810 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine-Proguanil combination (CQ+PROG)
Number of subjects: 0
Study 8511810 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 3596882 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMET)
Number of subjects: 9
Study 3596882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 31237187 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ASM (≥400 μm of maximum malapposed distance)
Number of subjects: 436
Study 31237187 — intervention group
Group type: COMPARATOR
Intervention: No ASM or ASM <400 μm of maximum malapposed distance
Number of subjects: 436
Study 31237187 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ASM (≥1 mm of maximum malapposed length)
Number of subjects: 436
Study 31237187 — intervention group
Group type: COMPARATOR
Intervention: No ASM or ASM <1 mm of maximum malapposed length
Number of subjects: 436
Study 28405705 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (GnRH antagonist)
Number of subjects: 6
Study 28405705 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (GnRH agonist)
Number of subjects: 6
Study 26068298 — intervention group
Group type: EXPERIMENTAL
Intervention: Baumgartner definition (low lean mass alone)
Number of subjects: 445
Study 26068298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruz‐Jentoft definition (low lean mass plus decreased functional performance)
Number of subjects: 445
Study 26068298 — intervention group
Group type: COMPARATOR
Intervention: Delmonico 1 definition
Number of subjects: 445
Study 26068298 — intervention group
Group type: COMPARATOR
Intervention: Fielding definition
Number of subjects: 445
Study 26068298 — intervention group
Group type: COMPARATOR
Intervention: Morley definition
Number of subjects: 445
Study 23507721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 16
Study 23507721 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 16
Study 21596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin 0.6% ophthalmic suspension
Number of subjects: 105
Study 21596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 105
Study 21596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 105
Study 20145786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate injections after knee arthroscopy
Number of subjects: 46
Study 20145786 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy alone
Number of subjects: 46
Study 16768551 — intervention group
Group type: EXPERIMENTAL
Intervention: suppression condition
Number of subjects: 205
Study 16768551 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 205
Study 16768551 — intervention group
Group type: EXPERIMENTAL
Intervention: distraction condition
Number of subjects: 205
Study 16768551 — intervention group
Group type: EXPERIMENTAL
Intervention: sensory focus condition
Number of subjects: 205
Study 15076173 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (plus indapamide if not contraindicated)
Number of subjects: 6105
Study 15076173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 10699768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable biopsy forceps
Number of subjects: 7740
Study 10699768 — intervention group
Group type: COMPARATOR
Intervention: Disposable biopsy forceps
Number of subjects: 7740
Study 9086985 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared medical record access
Number of subjects: 0
Study 9086985 — intervention group
Group type: COMPARATOR
Intervention: Educational materials only (Control)
Number of subjects: 0
Study 8450081 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 200 mg x 3 x 10 days
Number of subjects: 27
Study 8450081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg x 4 x 12 days
Number of subjects: 27
Study 8450081 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 27
Study 3096763 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg daily for four weeks
Number of subjects: 12
Study 3096763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12